scholarly journals The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review

2002 ◽  
Vol 6 (33) ◽  
Author(s):  
R. Garside ◽  
A. Round ◽  
K. Dalziel ◽  
K. Stein ◽  
P. Royle
Keyword(s):  
Systematic Review ◽  
Cost Effectiveness ◽  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia

scholarly journals Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol

BMJ Open ◽  
2019 ◽  
Vol 9 (9) ◽  
pp. e030092
Author(s):  
Janatani Balakumaran ◽  
Tanisha Birk ◽  
Breanne Golemiec ◽  
Wryan Helmeczi ◽  
Jeyanth Inkaran ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Myeloid Leukaemia ◽  
Tyrosine Kinase ◽  
Myeloid Leukaemia ◽  
Tyrosine Kinase Inhibitors ◽  
Health Effects ◽  
Bone Health ◽  
Kinase Inhibitors ◽  
Systematic Review Protocol ◽  
Review Protocol

IntroductionChronic Myeloid Leukaemia (CML) constitutes 15% of new adult leukaemia cases as well as 2%–3% of leukaemia in children under 15% and 9% of leukaemias in adolescents 15–19 years of age annually. The introduction of Tyrosine Kinase Inhibitors (TKI) therapy has dramatically improved survival in these patients, yet the off-target effects of this treatment may have long-term health impacts on CML survivors. The risk of adverse health outcomes is especially important in children, where TKI exposure may occur during critical windows of growth and puberty, and patients require treatment for prolonged periods of time. The aim of this systematic review protocol is to report on the methods used to conduct a systematic review to investigate the endometabolic and bone health effects of TKI therapy in CML.Methods and analysisSearches will be conducted in the Cochrane Central Register of Controlled Trials, EMBASE and MEDLINE from inception on August 1st, 2019. Searches may be updated while performing the systematic review to ensure new evidence is included if applicable. Grey literature search will include ClinicalTrials.gov and ProQuest Dissertations and Theses A&I. We will perform a meta-analysis if there are at least two studies reporting similar populations, interventions, methods and tracking the same outcome measures. The studies should also have similar age and sex distributions.Ethics and disseminationAs this is a systematic review protocol, it does not include patient data; therefore, Research Ethics Board approval is not indicated. The systematic review will be published in a peer-reviewed journal and presented at international conferences.PROSPERO registration numberCRD42018091175.

Model-Based Cost-Effectiveness Analyses for the Treatment of Chronic Myeloid Leukaemia: A Review and Summary of Challenges

2014 ◽  
Vol 32 (9) ◽  
pp. 853-864 ◽  
Author(s):  
Kevin Marsh ◽  
Peng Xu ◽  
Panagiotis Orfanos ◽  
Agnes Benedict ◽  
Kamal Desai ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Model Based
Sign in / Sign up

Export Citation Format

Share Document